Cost-effectiveness of the 21-gene recurrence score assay in the context of multifactorial decision making to guide chemotherapy for early-stage breast cancer

Reed SD, Dinan MA, Schulman KA, Lyman GH

Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

DOI
10.1038/gim.2012.119

Indexing Status
Subject indexing assigned by NLM

MeSH
Adult; Aged; Breast Neoplasms /drug therapy /economics /genetics /pathology; Chemotherapy, Adjuvant /economics; Cost-Benefit Analysis; Decision Making; Decision Trees; Female; Humans; Markov Chains; Middle Aged; Neoplasm Staging; Recurrence; Transcriptome

AccessionNumber
22013014996

Date bibliographic record published
01/05/2013